Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug developer MAP Pharmaceuticals (NASDAQ: MAPP) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at MAP and see what CAPS investors are saying about the stock right now.
MAP facts
|
Headquarters (founded) |
Mountain View, Calif. (2003) |
|
Market Cap |
$544.5 million |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month Revenue |
$3.6 million |
|
Management |
CEO Timothy Nelson (since 2005) |
|
Return on Capital (average, past 3 years) |
(57.4%) |
|
Cash/Debt |
$114.2 million / $0 |
|
Competitors |
GlaxoSmithKline (GSK 0.12%) |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 34% of the 96 members who have rated MAP believe the stock will underperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star BlacknGold, succinctly summed up the MAP bear case for our community:
MAP has no revenue and is losing large amounts of money each quarter (four in a row now). Before the recent financing deal it was worth less than $14 million on paper. Even now it's worth less than $60 million, which doesn't support a $540 million market cap.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
